These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17064997)

  • 1. Sézary cell counts in erythrodermic cutaneous T-cell lymphoma: implications for prognosis and staging.
    Vonderheid EC; Pena J; Nowell P
    Leuk Lymphoma; 2006 Sep; 47(9):1841-56. PubMed ID: 17064997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas.
    Vonderheid EC; Bernengo MG; Burg G; Duvic M; Heald P; Laroche L; Olsen E; Pittelkow M; Russell-Jones R; Takigawa M; Willemze R;
    J Am Acad Dermatol; 2002 Jan; 46(1):95-106. PubMed ID: 11756953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
    Vidulich KA; Talpur R; Bassett RL; Duvic M
    Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma.
    Scarisbrick JJ; Whittaker S; Evans AV; Fraser-Andrews EA; Child FJ; Dean A; Russell-Jones R
    Blood; 2001 Feb; 97(3):624-30. PubMed ID: 11157477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction.
    Gibson JF; Huang J; Liu KJ; Carlson KR; Foss F; Choi J; Edelson R; Hussong JW; Mohl R; Hill S; Girardi M
    J Am Acad Dermatol; 2016 May; 74(5):870-7. PubMed ID: 26874819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force.
    Scarisbrick JJ; Hodak E; Bagot M; Stranzenbach R; Stadler R; Ortiz-Romero PL; Papadavid E; Evison F; Knobler R; Quaglino P; Vermeer MH
    Eur J Cancer; 2018 Apr; 93():47-56. PubMed ID: 29477101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative flow cytometric identification of aberrant T cell clusters in erythrodermic cutaneous T cell lymphoma. Implications for staging and prognosis.
    Horna P; Deaver DM; Qin D; Moscinski LC; Sotomayor EM; Glass LF; Sokol L
    J Clin Pathol; 2014 May; 67(5):431-6. PubMed ID: 24319102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4
    Vonderheid EC; Hou JS
    Leuk Lymphoma; 2018 Feb; 59(2):330-339. PubMed ID: 28595473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
    Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
    Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated cutaneous T-cell lymphoma TNMB staging criteria fail to identify patients with Sézary syndrome with low blood burden.
    Chrisman LP; Trimark PF; Pang Y; Pease DR; Martinez-Escala ME; Nguyen WQ; Fernandez R; Griffin TL; Ayanruoh L; Hooper MJ; Zhou XA; Fu L; Wolniak KL; Guitart J
    Blood; 2024 Aug; 144(8):914-917. PubMed ID: 38848513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymph node classification systems in cutaneous T-cell lymphoma. Evidence for the utility of the Working Formulation of Non-Hodgkin's Lymphomas for Clinical Usage.
    Vonderheid EC; Diamond LW; van Vloten WA; Scheffer E; Meijer CJ; Cashell AW; Hardman JM; Lai SM; Hermans J; Matthews MJ
    Cancer; 1994 Jan; 73(1):207-18. PubMed ID: 8275427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
    Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
    J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
    Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
    Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of erythrodermic-CTCL.
    Shimoda T; Aoki M; Takezaki S; Futagami A; Inokuchi K; Sugisaki Y; Kawana S
    Leuk Lymphoma; 2006 Aug; 47(8):1708-10. PubMed ID: 16966295
    [No Abstract]   [Full Text] [Related]  

  • 18. Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker.
    Roelens M; de Masson A; Ram-Wolff C; Maki G; Cayuela JM; Marie-Cardine A; Bensussan A; Toubert A; Bagot M; Moins-Teisserenc H
    Br J Dermatol; 2020 Jun; 182(6):1415-1422. PubMed ID: 31487384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A modified staging classification for cutaneous T-cell lymphoma.
    Kashani-Sabet M; McMillan A; Zackheim HS
    J Am Acad Dermatol; 2001 Nov; 45(5):700-6. PubMed ID: 11606919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalization.
    el-Azhary RA; Bouwhuis SA
    Int J Dermatol; 2005 Jan; 44(1):25-8. PubMed ID: 15663654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.